Empagliflozin and Empagliflozin/Linagliptin Interaction

Drug interaction information between Empagliflozin and Empagliflozin/Linagliptin.

Empagliflozin and Empagliflozin/Linagliptin have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Empagliflozin and Empagliflozin/Linagliptin. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Empagliflozin

SGLT2 Inhibitor

Drug B

Empagliflozin/Linagliptin

SGLT2 / DPP-4 Combination

How They Interact

Both of these medicines increase how much you urinate. This can cause your body to lose too much water and become dehydrated.

FDA Label Information

Diuretics Clinical Impact Coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion.

Empagliflozin/Linagliptin Also Interacts With

View all Empagliflozin/Linagliptin interactions →

Frequently Asked Questions

What SPL severity band is on file for Empagliflozin + Empagliflozin/Linagliptin?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Empagliflozin/Linagliptin has 11 labeled pairs on file vs Empagliflozin's 10. In the minor band specifically: Empagliflozin has 5 (also Topiramate, Lithium, Phenytoin, Zonisamide); Empagliflozin/Linagliptin has 7 (also Topiramate, Lithium, Rifampin, Linagliptin).

What mechanism field is on file for Empagliflozin and Empagliflozin/Linagliptin?

Both of these medicines increase how much you urinate. This can cause your body to lose too much water and become dehydrated.

Empagliflozin/Linagliptin's labeled portfolio outnumbers Empagliflozin

SPL source-record counts only. This page's band is minor · classes on file: Empagliflozin (SGLT2 Inhibitor); Empagliflozin/Linagliptin (SGLT2 / DPP-4 Combination).

Empagliflozin

0 major · 5 moderate · 5 minor · 10 total

Empagliflozin/Linagliptin

0 major · 4 moderate · 7 minor · 11 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.